{
  "report_rows": [
    {
      "kpi": "Q2 2026 revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$2.01B vs. cons $2.02B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 adjusted EBITDA",
      "prediction": "IN-LINE",
      "answer": "pred ~$530M vs. cons $528M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 adjusted diluted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$0.85 vs. cons $0.84",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Adjusted EBITDA guidance",
      "prediction": "BETTER",
      "answer": "guide ~$2.16B vs. cons $2.15B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted diluted EPS guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~$3.51 vs. cons $3.51 (FY2026)",
      "confidence": "HIGH"
    },
    {
      "kpi": "Revenue growth guidance",
      "prediction": "LOWER",
      "answer": "guide ~3.5% vs. cons 3.9% (FY2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 1.6,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 0.7,
  "day5_path": "FADE",
  "day5_rationale": "Initial relief from the ~$0.85 EPS result versus $0.84 consensus and improving core margins should fade because FY2026 EPS guidance of ~$3.51 versus $3.51 consensus leaves little revision upside, while ~3.5% revenue-growth guidance trails the 3.9% consensus.",
  "day5_confidence": "MEDIUM"
}